Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer

被引:54
作者
Zimmer, LA
McCook, B
Meltzer, C
Fukui, M
Bascom, D
Snyderman, C
Townsend, DW
Johnson, JT
机构
[1] Univ Pittsburgh, Ctr Med, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Ctr Med, Dept Radiol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Ctr Med, Dept Psychiat, Pittsburgh, PA 15213 USA
关键词
D O I
10.1067/mhn.2003.74
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVE: The study goal was to evaluate the use of combined positron emission tomography/computed tomography (PET/CT) imaging for localization of recurrent disease in thyroid cancer patients. STUDY DESIGN AND SETTING: Eight patients with suspected recurrence of thyroid cancer on the basis of elevated serum thyroglobulin or calcitonin levels underwent combined PET/CT imaging on a prototype device. All 8 patients had previously undergone total thyroidectomy and (131)1 ablation for thyroid carcinoma. Patients with papillary carcinoma had negative (131)1 scans. RESULTS: Eight patients underwent combined PET/CT scanning. Four (50%) of 8 patients underwent PET/CT indicating recurrence in the head and neck. A total of 11 lesions in these 4 patients were suspicious for recurrence on combined PET/CT imaging. Three patients with 8 lesions suspicious for recurrence on PET/CT underwent surgical,removal of disease. All 3 patients had pathologic confirmation of recurrence, with 6 (75.0%) of 8 lesions being positive. CONCLUSION: Combined PET/CT imaging is a valuable tool for the diagnosis and anatomic localization of recurrent thyroid cancer.
引用
收藏
页码:178 / 184
页数:7
相关论文
共 20 条
[1]  
Adams S, 1998, EUR J NUCL MED, V25, P79
[2]   THE COMPARATIVE VALUE OF SERUM THYROGLOBULIN MEASUREMENTS AND I-131 TOTAL-BODY SCANS IN THE FOLLOW-UP-STUDY OF PATIENTS WITH TREATED DIFFERENTIATED THYROID-CANCER [J].
ASHCRAFT, MW ;
VANHERLE, AJ .
AMERICAN JOURNAL OF MEDICINE, 1981, 71 (05) :806-814
[3]  
Beyer T, 2000, J NUCL MED, V41, P1369
[4]   The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer [J].
Brandt-Mainz, K ;
Müller, SP ;
Görges, R ;
Saller, B ;
Bockisch, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (05) :490-496
[5]  
Casara D, 1999, TUMORI, V85, P122
[6]   Image analysis in patients with cancer studied with a combined PET and CT scanner [J].
Charron, M ;
Beyer, T ;
Bohnen, NN ;
Kinahan, PE ;
Dachille, M ;
Jerin, J ;
Nutt, R ;
Meltzer, CC ;
Villemagne, V ;
Townsend, DW .
CLINICAL NUCLEAR MEDICINE, 2000, 25 (11) :905-910
[7]   Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer [J].
Dietlein, M ;
Scheidhauer, K ;
Voth, E ;
Theissen, P ;
Schicha, H .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (11) :1342-1348
[8]  
Feine U, 1996, J NUCL MED, V37, P1468
[9]  
Freitas John E., 1998, V1998, P83
[10]   Imaging in thyroid cancer [J].
Galloway, RJ ;
Smallridge, RC .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1996, 25 (01) :93-+